The tweet was deleted by the author.
But we saved everything 🙂.
Monte Rosa Therapeutics CEO Markus Warmuth delivers an update on the company pipeline at the TD Cowen Health Care Conference.
Warmuth outlines recent progress and clinical data, focusing on programs targeting NEK7 and GSPT1-directed degraders. The presentation aims to showcase advances in Monte Rosa Therapeutics' therapeutic candidates and their development strategy.